Trial Profile
A Phase 1 Study of Neratinib in Combination With Temsirolimus in Subjects With Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Temsirolimus (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer; Puma Biotechnology
- 09 Dec 2013 Results published in the Journal of Clinical Oncology.
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2012 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.